Skip to Main Content

Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. As you know, a prescription is not required. Our choice today is pumpkin spice. So feel free to indulge as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something saucy. …

After 18 months of talks, a compromise was reached on a proposal to waive intellectual property rights for Covid-19 medical products, STAT reports, citing this document, which was confirmed by a trade official familiar with the negotiations. For the moment, the agreement reached between the European Union, South Africa, India, and the United States, only covers vaccines, but in six months could be extended to therapies and diagnostics. Nonetheless, patient advocates criticized the delay and also noted the agreement would not grant technology transfers, so that other manufacturers could produce versions of a Covid-19 shot.


Pfizer (PFE) and BioNTech (BNTX) asked the U.S. Food and Drug Administration to authorize a second booster dose of their Covid-19 vaccine for people 65 years and older, The Wall Street Journal notes. The agency is expected to make a decision in time for the Biden administration to begin a potential fall vaccine campaign. The FDA has been reviewing data and looking at potentially authorizing a fourth dose of the shot for use in the fall. So far, health authorities have cleared booster doses for children as young as 12 years of age, at least five months after they finished their first round of vaccination.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.